These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38955418)

  • 41. Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study.
    Reinmuth N; Juan-Vidal O; Kowalski D; Bryl M; Kryzhanivska A; Vicente D; Horváth Z; Gálffy G; Csánky E; Pápai Székely Z; Vynnychenko I; Armstrong J; Dalvi T; Xie M; Iyer S; Shrestha Y; Jiang H; Bondarenko I
    Clin Cancer Res; 2024 Sep; 30(18):4055-4067. PubMed ID: 39017667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
    Socinski MA; Kaye FJ; Spigel DR; Kudrik FJ; Ponce S; Ellis PM; Majem M; Lorigan P; Gandhi L; Gutierrez ME; Nepert D; Corral J; Ares LP
    Clin Lung Cancer; 2017 Jan; 18(1):68-76.e2. PubMed ID: 28341109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.
    Imai H; Mori K; Watase N; Fujimoto S; Kaira K; Yamada M; Minato K
    Can Respir J; 2016; 2016():5405810. PubMed ID: 27445549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer.
    Armstrong SA; Liu SV
    Curr Oncol Rep; 2020 Feb; 22(2):20. PubMed ID: 32034529
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
    Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
    Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).
    Nishio M; Sugawara S; Atagi S; Akamatsu H; Sakai H; Okamoto I; Takayama K; Hayashi H; Nakagawa Y; Kawakami T
    Clin Lung Cancer; 2019 Nov; 20(6):469-476.e1. PubMed ID: 31466854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
    Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
    J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
    Reck M; Mok TSK; Mansfield A; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair M; Garassino MC; de Castro Junior G; Bischoff H; Lam S; Cardona A; Morris S; Liu SV
    J Thorac Oncol; 2022 Sep; 17(9):1122-1129. PubMed ID: 35764236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review.
    Zhou N; Chen Y; Huang Q; Jiang L; Liao H; Gou H; Lu Y; Che G; Zhang Y
    Front Immunol; 2023; 14():1111325. PubMed ID: 36911701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
    Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
    Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.
    Kim H; Choi E; Heo MH; Kim JY; Park KU
    Oncology; 2022; 100(6):313-319. PubMed ID: 35390786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.
    Lee S; Shim HS; Ahn BC; Lim SM; Kim HR; Cho BC; Hong MH
    Cancer Immunol Immunother; 2022 May; 71(5):1093-1101. PubMed ID: 34568975
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
    Shibaki R; Fujimoto D; Miyauchi E; Tsukita Y; Nakachi I; Arai D; Sakata Y; Shingu N; Shimokawa T; Kijima T; Tamiya M; Kawana S; Hara S; Saito G; Sato Y; Yokoyama T; Sakata S; Taniguchi Y; Hata A; Matsumoto H; Yamaguchi T; Yamamoto N
    Lung Cancer; 2024 Oct; 196():107958. PubMed ID: 39312871
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.
    Hatfield LA; Huskamp HA; Lamont EB
    J Oncol Pract; 2016 Jul; 12(7):666-73. PubMed ID: 27352949
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
    Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE
    J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.
    Peressini M; Garcia-Campelo R; Massuti B; Martí C; Cobo M; Gutiérrez V; Dómine M; Fuentes J; Majem M; de Castro J; Córdoba JF; Diz MP; Isla D; Esteban E; Carcereny E; Vila L; Moreno-Vega A; Ros S; Moreno A; García FJ; Huidobro G; Aguado C; Cebey-López V; Valdivia J; Palmero R; Lianes P; López-Brea M; Vidal OJ; Provencio M; Arriola E; Baena J; Herrera M; Bote H; Molero M; Adradas V; Ponce-Aix S; Nuñez-Buiza A; Ucero Á; Hernandez S; Lopez-Rios F; Conde E; Paz-Ares L; Zugazagoitia J
    Clin Cancer Res; 2024 Jul; 30(14):3036-3049. PubMed ID: 38630755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
    Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
    BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.